Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/7355
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP-
dc.contributor.authorZAGO, Vanessa Helena de Souza-
dc.contributor.authorTANUS-SANTOS, Jose Eduardo-
dc.contributor.authorDANELON, Mirian Regina Gardin-
dc.contributor.authorPARRA, Eliane Soler-
dc.contributor.authorALEXANDRE, Fernanda-
dc.contributor.authorVIEIRA, Isabela Calanca-
dc.contributor.authorPANZOLDO, Natalia Baratella-
dc.contributor.authorD'ALEXANDRI, Fabio Luis-
dc.contributor.authorQUINTAO, Eder Carlos Rocha-
dc.contributor.authorFARIA, Eliana Cotta de-
dc.date.accessioned2014-09-30T14:38:10Z-
dc.date.available2014-09-30T14:38:10Z-
dc.date.issued2014-
dc.identifier.citationINTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, v.52, n.4, p.277-283, 2014-
dc.identifier.issn0946-1965-
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/7355-
dc.description.abstractRegardless of its effect on the concentrations of serum cholesterol, statins exert pleiotropic effects, including the regulation of endothelial function, reduced oxidative stress and inflammation, as well as a slight improvement in the concentrations of high density lipoprotein (HDL). However, its role on the composition of HDL is not yet established. The aim of this study was to evaluate the composition of HDL subfractions, HDL2 and HDL3, after 14 days of placebo and atorvastatin (10 mg/day) use in 30 asymptomatic volunteers. The serum parameters and the HDL subfractions compositions were determined using radiometric, nephelometric and biochemical enzymatic methods. We observed significant reductions of total cholesterol, low density lipoprotein (LDL) and apolipoprotein B-100 by 28%, 40% and 38%, respectively. The analyses of chemical composition of the subfractions revealed a lower lipid protein ratio in HDL2, suggesting enrichment in proteins, and also lower in HDL3, probably by an increase in the number of particles. Several mechanisms can be suggested for the effects observed after the use of atorvastatin, such as a possible action on the reverse cholesterol transport (decreased activity of hepatic lipase and increased phospholipid transfer protein, PLTP), which would explain the enrichment of HDL. The results suggest that statin use may be relevant in the primary prevention of atherosclerosis not only by its lowering effect on LDL-cholesterol and its anti-inflammatory effect but also by beneficial changes in HDL subfractions.-
dc.description.sponsorshipFundacao de Amparo Pesquisa do Estado de Sao Paulo (FAPESP) [2006/60585-9]-
dc.description.sponsorshipConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) [471380/2008-3]-
dc.language.isoeng-
dc.publisherDUSTRI-VERLAG DR KARL FEISTLE-
dc.relation.ispartofInternational Journal of Clinical Pharmacology and Therapeutics-
dc.rightsrestrictedAccess-
dc.subjecthigh density lipoprotein-
dc.subjectstatins-
dc.subjectatherosclerosis-
dc.subject.otherlecithin-cholesterol acyltransferase-
dc.subject.otherapolipoprotein-a-i-
dc.subject.othertherapeutic target-
dc.subject.othertransfer protein-
dc.subject.otherester transfer-
dc.subject.otherparticle-size-
dc.subject.otherstatins-
dc.subject.otherplasma-
dc.subject.otherhypercholesterolemia-
dc.subject.otheratherosclerosis-
dc.titleChemical modification of high density lipoprotein subfractions - HDL2 and HDL3 - after use of atorvastatin-
dc.typearticle-
dc.rights.holderCopyright DUSTRI-VERLAG DR KARL FEISTLE-
dc.identifier.doi10.5414/CP201742-
dc.identifier.pmid24548977-
dc.subject.wosPharmacology & Pharmacy-
dc.type.categoryoriginal article-
dc.type.versionpublishedVersion-
hcfmusp.author.externalZAGO, Vanessa Helena de Souza:Univ Estadual Campinas, Fac Med Sci, Lipid Lab, Dept Clin Pathol, BR-13084971 Campinas, SP, Brazil; Univ Estadual Campinas, Fac Med Sci, Ctr Med & Expt Surg, BR-13084971 Campinas, SP, Brazil-
hcfmusp.author.externalTANUS-SANTOS, Jose Eduardo:Univ Sao Paulo, Fac Med Sci, Dept Pharmacol, Sao Paulo, Brazil-
hcfmusp.author.externalDANELON, Mirian Regina Gardin:Univ Estadual Campinas, Fac Med Sci, Lipid Lab, Dept Clin Pathol, BR-13084971 Campinas, SP, Brazil; Univ Estadual Campinas, Fac Med Sci, Ctr Med & Expt Surg, BR-13084971 Campinas, SP, Brazil-
hcfmusp.author.externalPARRA, Eliane Soler:Univ Estadual Campinas, Fac Med Sci, Lipid Lab, Dept Clin Pathol, BR-13084971 Campinas, SP, Brazil; Univ Estadual Campinas, Fac Med Sci, Ctr Med & Expt Surg, BR-13084971 Campinas, SP, Brazil-
hcfmusp.author.externalALEXANDRE, Fernanda:Univ Estadual Campinas, Fac Med Sci, Lipid Lab, Dept Clin Pathol, BR-13084971 Campinas, SP, Brazil; Univ Estadual Campinas, Fac Med Sci, Ctr Med & Expt Surg, BR-13084971 Campinas, SP, Brazil-
hcfmusp.author.externalVIEIRA, Isabela Calanca:Univ Estadual Campinas, Fac Med Sci, Lipid Lab, Dept Clin Pathol, BR-13084971 Campinas, SP, Brazil; Univ Estadual Campinas, Fac Med Sci, Ctr Med & Expt Surg, BR-13084971 Campinas, SP, Brazil-
hcfmusp.author.externalPANZOLDO, Natalia Baratella:Univ Estadual Campinas, Fac Med Sci, Lipid Lab, Dept Clin Pathol, BR-13084971 Campinas, SP, Brazil; Univ Estadual Campinas, Fac Med Sci, Ctr Med & Expt Surg, BR-13084971 Campinas, SP, Brazil-
hcfmusp.author.externalD'ALEXANDRI, Fabio Luis:Univ Estadual Campinas, Fac Med Sci, Lipid Lab, Dept Clin Pathol, BR-13084971 Campinas, SP, Brazil; Univ Estadual Campinas, Fac Med Sci, Ctr Med & Expt Surg, BR-13084971 Campinas, SP, Brazil-
hcfmusp.author.externalFARIA, Eliana Cotta de:Univ Estadual Campinas, Fac Med Sci, Lipid Lab, Dept Clin Pathol, BR-13084971 Campinas, SP, Brazil; Univ Estadual Campinas, Fac Med Sci, Ctr Med & Expt Surg, BR-13084971 Campinas, SP, Brazil-
hcfmusp.description.beginpage277-
hcfmusp.description.endpage283-
hcfmusp.description.issue4-
hcfmusp.description.volume52-
hcfmusp.origemWOS-
hcfmusp.origem.idWOS:000335099000003-
hcfmusp.origem.id2-s2.0-84897053083-
hcfmusp.publisher.cityDEISENHOFEN-MUENCHEN-
hcfmusp.publisher.countryGERMANY-
hcfmusp.relation.referenceArcanjo Christiane Lopes, 2005, Arq Bras Endocrinol Metabol, V49, P951, DOI 10.1590/S0004-27302005000600015-
hcfmusp.relation.referenceAsztalos BF, 2006, ATHEROSCLEROSIS, V188, P59, DOI 10.1016/j.atherosclerosis.2005.10.018-
hcfmusp.relation.referenceBarter PJ, 2010, J LIPID RES, V51, P1546, DOI 10.1194/jlr.P002816-
hcfmusp.relation.referenceBarter PJ, 2006, CURR OPIN LIPIDOL, V17, P399, DOI 10.1097/01.mol.0000236365.40969.af-
hcfmusp.relation.referenceBellanger N, 2012, ATHEROSCLEROSIS, V221, P160, DOI 10.1016/j.atherosclerosis.2011.12.027-
hcfmusp.relation.referenceBlum A, 2009, ATHEROSCLEROSIS, V203, P325, DOI 10.1016/j.atherosclerosis.2008.08.022-
hcfmusp.relation.referenceBoizel R, 2000, DIABETES CARE, V23, P1679, DOI 10.2337/diacare.23.11.1679-
hcfmusp.relation.referenceCampo VL, 2007, QUIM NOVA, V30, P425, DOI 10.1590/S0100-40422007000200033-
hcfmusp.relation.referenceCatalano G, 2009, ARTERIOSCL THROM VAS, V29, P268, DOI 10.1161/ATVBAHA.108.179416-
hcfmusp.relation.referenceCho KH, 2009, BMB REP, V42, P393-
hcfmusp.relation.referenceChong PH, 2001, AM J MED, V111, P390, DOI 10.1016/S0002-9343(01)00870-1-
hcfmusp.relation.referenceDaniels TF, 2009, INT J BIOL SCI, V5, P474-
hcfmusp.relation.referenceDeshmukh HA, 2012, J LIPID RES, V53, P1000, DOI 10.1194/jlr.P021113-
hcfmusp.relation.referenceEYRE J, 1981, CLIN CHIM ACTA, V114, P225, DOI 10.1016/0009-8981(81)90395-8-
hcfmusp.relation.referenceFRIEDEWA.WT, 1972, CLIN CHEM, V18, P499-
hcfmusp.relation.referenceArca M, 2007, DRUGS, V67, P29, DOI 10.2165/00003495-200767001-00004-
hcfmusp.relation.referenceGoodman LS, 1990, GOODMAN GILMANS PHAR-
hcfmusp.relation.referenceGuerin M, 2000, ARTERIOSCL THROM VAS, V20, P189-
hcfmusp.relation.referenceHarangi M, 2009, TRANSL RES, V153, P190, DOI 10.1016/j.trsl.2009.01.007-
hcfmusp.relation.referenceIgarashi J, 2007, BRIT J PHARMACOL, V150, P470, DOI 10.1038/sj.bjp.0707114-
hcfmusp.relation.referenceJacobsen W, 2000, DRUG METAB DISPOS, V28, P1369-
hcfmusp.relation.referenceJOHANSSON J, 1991, ATHEROSCLEROSIS, V91, P175, DOI 10.1016/0021-9150(91)90165-Y-
hcfmusp.relation.referenceJukema JW, 2012, J AM COLL CARDIOL-
hcfmusp.relation.referenceKAGAMI A, 1993, CLIN BIOCHEM, V26, P101, DOI 10.1016/0009-9120(93)90036-6-
hcfmusp.relation.referenceKapur Navin K, 2008, Vasc Health Risk Manag, V4, P39, DOI 10.2147/vhrm.2008.04.01.39-
hcfmusp.relation.referenceKassai A, 2007, CLIN BIOCHEM, V40, P1, DOI 10.1016/j.clinbiochem.2006.05.016-
hcfmusp.relation.referenceKontush A, 2004, ARTERIOSCL THROM VAS, V24, P526, DOI 10.1161/01.ATV.0000118276.87061.00-
hcfmusp.relation.referenceKontush A, 2006, PHARMACOL REV, V58, P342, DOI 10.1124/pr.58.3.1-
hcfmusp.relation.referenceLennernas H, 2003, CLIN PHARMACOKINET, V42, P1141, DOI 10.2165/00003088-200342130-00005-
hcfmusp.relation.referenceMackey RH, 2002, AM J CARDIOL, V90, p71I-
hcfmusp.relation.referenceMaejima T, 2004, BIOCHEM BIOPH RES CO, V324, P835, DOI 10.1016/j.bbrc.2004.09.122-
hcfmusp.relation.referenceMassey JB, 2008, BBA-MOL CELL BIOL L, V1781, P245, DOI 10.1016/j.bbalip.2008.03.003-
hcfmusp.relation.referenceMcTaggart F, 2008, CARDIOVASC DRUG THER, V22, P321, DOI 10.1007/s10557-008-6113-z-
hcfmusp.relation.referenceNatick M, 1996, CLIN CHEM, V42, P424-
hcfmusp.relation.referenceRosenson RS, 2002, AM J CARDIOL, V90, P89, DOI 10.1016/S0002-9149(02)02427-X-
hcfmusp.relation.referenceSchonbeck U, 2004, CIRCULATION, V109, P1118-
hcfmusp.relation.referenceSettasatian N, 2001, J BIOL CHEM, V276, P26898, DOI 10.1074/jbc.M010708200-
hcfmusp.relation.referenceShishehbor MH, 2003, CIRCULATION, V108, P426, DOI 10.1161/01.CIR.0000080895.05158.8B-
hcfmusp.relation.referenceSingh IM, 2007, JAMA-J AM MED ASSOC, V298, P786, DOI 10.1001/jama.298.7.786-
hcfmusp.relation.referenceSTAMPFER MJ, 1991, NEW ENGL J MED, V325, P373, DOI 10.1056/NEJM199108083250601-
hcfmusp.relation.referenceYamashita S, 2010, J ATHEROSCLER THROMB, V17, P436-
dc.description.indexMEDLINE-
hcfmusp.remissive.sponsorshipCNPq-
hcfmusp.remissive.sponsorshipFAPESP-
hcfmusp.citation.scopus3-
hcfmusp.scopus.lastupdate2022-05-20-
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/MCM
Departamento de Clínica Médica - FM/MCM

Artigos e Materiais de Revistas Científicas - LIM/10
LIM/10 - Laboratório de Lípides


Files in This Item:
File Description SizeFormat 
art_ZAGO_Chemical_modification_of_high_density_lipoprotein_subfractions_HDL2_2014.PDF
  Restricted Access
publishedVersion (English) 438.63 kBAdobe PDFView/Open Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.